UKUK

The fifteen-minute genome

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its data on 17 February at the “Advances in Genome Biology and Technology” meeting in Marco Island, Florida (US). The firm’s “Strand sequencing” technology identifies bases in real time by measuring electrical conductivity as a DNA strand is fed through a biological nanopore. The Grid­ION system comprises scalable nodes that contain array chips for multi-nano­pore sequencing of single strands, allowing the user to choose a run time between minutes and days. The initial version, which will be available this year, is designed for real-time sequencing by 2,000 nanopores at once to deliver tens of giga­bits of data per 24 hours. Oxford said that an 8,000-nanopore GridION configuration, which the company asserts could perform whole genome sequencing in 15 minutes, will be available in early 2013. Oxford Nanopore said that GridION will be sold at a price-per-base “as competitive as other leading systems at launch.” The company also said that MinION, a miniature version of the platform, will be available this year. Nano­pore sequencing has the potential to achieve read lengths of up to 10,000 bases, ten times more than the best current platforms. Additionally, the technology promises more cost-effectiveness than current sequencing methods which all are dependent on costly fluorescence cameras and labels. A second application dubbed “Exonuclease sequencing”, which includes enzymatic DNA cleavage, has been partnered with US firm Illumina Inc.

UKUK

19.08.2011

Brussels – While worldwide stock exchanges took a beating in late July and early August, European biotech stocks plunged even more. Stocks of majors like Roche, Novartis and GSK lost more than 10% in the first week of the month,...

Austria, UKUK

17.08.2011

London/Pasching –GE Healthcare vamps up its biopharmaceutical capabilities. The U.K. based unit of the U.S. technology giant General Electric, announced that it has reached an agreement to acquire the Austrian PAA Laboratories....

UKUK

16.08.2011

London – The International Multiple Sclerosis Genetics Consortium, led by the Universities of Cambridge and Oxford and funded by the Wellcome Trust, has identified 29 new genetic variations linked to multiple sclerosis (MS). The...

UKUK

16.08.2011

London – A consortium led by British gene medicince company Ark Therapeutics Group plc has received a EUR5.3m grant from the European Commission’s 7th Framework Programme to fund research to combine Ark’s technology covering...

UKUK

09.08.2011

London - Patents on biomarkers are necessary to encourage innovation and investment in the UK DNA diagnostics market. This is the conclusion of a report from the UK Human Genetics Commission. The paper "Intellectual Property and...

UKUK

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult...

UKUK

07.07.2011

The British analytics specialist LGC Ltd. will buy its peer, KBioscience, for an undisclosed sum. The acquisition of KBioscience brings LGC expertise in genotyping services, chemistry and complements its genomic services...

Displaying results 31 to 40 out of 396

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/3/article/the-fifteen-minute-genome.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products